A CXCR4-specific small molecule inhibitor, AMD3100 (Plerixafor), was first designed as an HIV-1 entry inhibitor, but is currently administered to mobilize hematopoietic stem cells from the bone marrow [21] and also shows promise as an anti-cancer therapeutic [22]. This evidence concerns the gene CXCR4 and cancer.